. 2022 Aug 19;81:104463. doi: 10.1016/j.amsu.2022.104463

Table 1.

Showing pre-operative desensitization protocol.

Protocol Day	Desensitization Therapy	Anti-A & Anti-B titer level and CD-19 count
Pre-LT:day-23	Inj. Rituximab 375 mg/m² = 700mg I.V slow
Pre-LT:day-23	Inj. Bortezomib 1.3 mg/m² = 2mg I.V slow
Pre-LT:day-20	Inj. Bortezomib 1.3 mg/m² = 2mg Subcutaneous(S/C)
Pre-LT:day −16	Inj. Bortezomib 1.3 mg/m² = 2mg S/C
Pre-LT:day −13	Inj. Bortezomib 1.3 mg/m² = 2mg S/C
Pre-LT:day-7	Tab. Mycophenolate mofetil 500 mg twice daily
Pre-LT:day-7	Tab. Tacrolimus 1 mg twice daily
Pre-LT:day-5	Therapeutic plasmapheresis	Anti-A & Anti-B titer level = 1:32
Pre-LT:day-3	Therapeutic plasmapheresis	Anti-A & Anti-B titer level = 1:16
Pre-LT: day-1	Therapeutic plasmapheresis	Anti-A & Anti-B titer level = 1:4
Pre-LT: day-1	Therapeutic plasmapheresis	CD 19 activity = 1.6%
Operative day (day-0)	LT procedure performed
Operative day (day-0)	Inj. Basiliximab 0.8 gm/kg I.V (During anhepatic phase)
Post-LT:day-15		Anti-A & Anti-B titer level = 1:16
Post-LT:day-15		CD 19 activity = < 3%
Post-LT:3 months		Anti-A & Anti-B titer level = 1:16